Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid-Induced Constipation Clear all
Completed Phase 2 Interventional Results available

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

NCT00600119
View directory record Official record
Conditions
Opioid Induced Constipation (OIC)
Interventions
placebo, NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 28, 2026, 8:36 PM EDT
Not listed Phase 2Phase 3 Interventional

Naloxegol and Opioid-induced Constipation

NCT03316859
View directory record Official record
Conditions
Constipation, Constipation Drug Induced
Interventions
Naloxegol 25 MG, Placebo pill
Drug · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00241722
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
143
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
77
States / cities
Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01336205
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Usual care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
169
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

NCT01186770
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

NCT00365820
View directory record Official record
Conditions
Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Timeline
2006 – 2007
U.S. locations
59
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 4 Interventional Results available

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

NCT00672139
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 28, 2026, 8:36 PM EDT
Terminated Phase 4 Interventional

Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients

NCT00799201
View directory record Official record
Conditions
Constipation, Analgesia
Interventions
Naloxone and Docusate
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 2 Interventional

ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)

NCT01100151
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
RDC-1036 (ALKS 37), Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Sheffield, Alabama • Anaheim, California • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

NCT01040637
View directory record Official record
Conditions
Healthy, Opioid-induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Pasadena, California • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

NCT00595946
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
94
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Terminated Phase 2 Interventional Results available

Naloxegol in Cancer Opioid-Induced Constipation

NCT02745353
View directory record Official record
Conditions
Constipation
Interventions
naloxegol
Drug
Lead sponsor
Joseph Ma
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Withdrawn Phase 4 Interventional

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

NCT00858754
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Laguna Hills, California • Lancaster, California • Flat Rock, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

NCT01427270
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
170
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Not applicable Interventional Results available

Compassionate Use Study of Methylnaltrexone

NCT01368562
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
94
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00259922
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
Placebo, Alvimopan, Alviompan
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Sep 28, 2026, 8:36 PM EDT
Completed No phase listed Observational

Longitudinal Study of Patients With Opioid-Induced Constipation

NCT01928953
View directory record Official record
Conditions
Patients With Opioid Induced Constipation
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

NCT00640146
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 28, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 8:36 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00414024
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Timeline
2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 28, 2026, 8:36 PM EDT